Featured Topics
Lead story
Other featured articles
-
Biosimilar Drugs Underutilized Due to Commercial Insurance Restrictions
The first study to examine biosimilar drivers finds commercial insurers limit use in almost 20% of cases.
Posted in -
Schaeffer Research Director Testifies at Congressional Hearing on Biomedical Innovation and Patient Access
Darius Lakdawalla was part of a panel of experts called upon by the U.S. House Ways and Means Subcommittee on Health.
Posted in -
COVID-19’s Total Cost to the U.S. Economy Will Reach $14 Trillion by End of 2023
Workplace absences, along with sales lost due to the cessation of brick-and-mortar retail shopping, airline travel and public gatherings, contributed the most.
Posted in -
Benefits of Medicare Coverage for Weight Loss Drugs
The cumulative social benefits from Medicare coverage for new obesity treatments over the next 10 years would reach almost $1 trillion, or roughly $100 billion per year.
Posted in
The Leonard D. Schaeffer Center for Health Policy & Economics, one of the nation’s premier policy centers, measurably improves value in health through evidence-based policy solutions, research excellence, and private- and public-sector engagement.
about
Our Policy Areas
From aging to drug pricing to health disparities, Schaeffer Center experts are advancing research to inform policy. Learn about the areas we work in.
Learn MoreWork & Study at USC
The Schaeffer Center develops innovators for positions in higher education, research, government and healthcare through degree programs and postgraduate opportunities.
Learn More